Forte Biosciences (FBRX) Net Cash Flow (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Net Cash Flow data on file, last reported at -$18.7 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$18.7 million, down 179.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (down 19.87% YoY), and the FY2025 annual result was $54.7 million, up 467.55% from the prior year.
• Net Cash Flow declined to -$18.7 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $60.3 million in Q2 2025 and troughed at -$18.7 million in Q1 2026.
• A 5-year average of $1.5 million and a median of -$5.2 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1113.93% in 2025 and fell as far as 380.14% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$2.9 million in 2022, then sank by 207.33% to -$9.1 million in 2023, then soared by 164.91% to $5.9 million in 2024, then tumbled by 380.14% to -$16.5 million in 2025, then fell by 13.71% to -$18.7 million in 2026.
• Business Quant data shows FBRX's Net Cash Flow at -$18.7 million in Q1 2026, -$16.5 million in Q4 2025, and -$12.7 million in Q3 2025.